UAMS.EDU

Zafgen’s Beloranib IND gets complete clinical hold after second death

Zafgen, a Boston-based biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, has received verbal notice from the FDA that its beloranib investigational new drug (IND) application has been placed on complete clinical hold, affecting the ongoing open label extension (OLE) portion of the pivotal phase III ZAF-311 bestPWS clinical trial in patients with Prader-Willi syndrome (PWS). A complete clinical hold is an order that the FDA issues to a sponsor to suspend all clinical work requested under the company’s IND application.

 

 

Link to full article: http://news.centerwatch.com/2015/12/07/zafgens-beloranib-ind-gets-complete-clinical-hold-after-second-death/